Page 23 - Exact Sciences News Today

/PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that it has filed a lawsuit...

Madison-based Exact Sciences says St. Louis-based Geneoscopys new ColoSense test violates a patent on collecting and processing stool samples.

Exact Sciences Corp (NASDAQ: EXAS) filed a patent infringement lawsuit against Geneoscopy in the U.S.

Madison-based Exact Sciences says St. Louis-based Geneoscopys new ColoSense test violates a patent on collecting and processing stool samples.

Madison-based Exact Sciences says St. Louis-based Geneoscopys new ColoSense test violates a patent on collecting and processing stool samples.

Madison-based Exact Sciences says St. Louis-based Geneoscopys new ColoSense test violates a patent on collecting and processing stool samples.

Madison-based Exact Sciences says St. Louis-based Geneoscopys new ColoSense test violates a patent on collecting and processing stool samples.

DURHAM, N.C.--(BUSINESS WIRE)--#GeneCentric--GeneCentric Therapeutics, a company making precision medicine more precise through RNA-based diagnostics, today announced the appointment of Prasanth Reddy, MD, MPH, FACP, and Don Hardison as independent directors of its Board of Directors.Dr. Reddy is triple board-certif...

Abrdn plc boosted its stake in shares of Exact Sciences Co. (NASDAQ:EXAS – Free Report) by 7.3% in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 68,620 shares of the medical research company’s stock after purchasing an additional 4,643 shares during the quarter. abrdn […]

Operator: Good afternoon, ladies and gentlemen, and welcome to the Exact Sciences Third Quarter 2023 Earnings Conference Call.